Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nano-curcumin for prevention of radiotherapy-induced skin reactions in breast cancer
IRCT20200513047427N1Phase 3Completed
- Sponsor
- Kashan University of Medical Sciences
- Start
- Sep 2020
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in radiodermatitis comparing Nano-curcumin with Placebo (2 arms). Primary endpoint: Radiotherapy-induced skin reaction severity. Started Sep 2020; status: completed.
02
Drugs
nanocurcumin
03
Conditions
radiodermatitis
Beyond the preview
Go deeper on IRCT20200513047427N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200513047427N1.